Soluble ectodomain fragments of MET and uses thereof
AssigneeMedical Research Council
InventorErmanno Gherardi
Life of this patent
Estimating the term…
Abstract
The invention relates a fragment derived from the MET ectodomain which the inventors have found is capable, in monomer form, of binding to HGF/SF either in the presence or absence of heparin. The availability of soluble, monomeric forms of the MET receptor enabled studies of its solution properties and HGF/SF binding and provides an assay comprising the steps of (a) providing a MET ectodomain fragment; (b) providing an agent; and (c) determining the extent to which the agent interacts with said fragment.
Claims13
An assay method for determining whether an agent binds to a MET ectodomain fragment in monomeric form or for determining whether said agent disrupts binding of said ectodomain fragment to hepatocyte growth factor/scatter factor (HGF/SF) or for determining whether said agent disrupts the binding of said ectodomain fragment to a fragment of HGF/SF which otherwise binds said ectodomain which comprises:
- (a) providing a MET ectodomain fragment in monomeric form, wherein said MET is SEQ ID NO:
- 1 or the A320V variant thereof and wherein said MET ectodomain fragment comprises amino acids 25-928 of the MET ectodomain or is an N-terminal fragment of amino acids 25-928 of the MET ectodomain having 495 amino acids;
- (b) providing an agent;
- and
- (c) determining whether the agent binds to said fragment or disrupts the binding of said fragment to hepatocyte growth factor/scatter factor (HGF/SF) or a fragment of HGF/SF which binds to said ectodomain, wherein said HGF/SF is human HGF/SF recorded as SEQ ID NO:
- 2.
An isolated MET ectodomain fragment in monomeric form, wherein said MET is SEQ ID NO:
- 1 or the A320V variant thereof and wherein said MET ectodomain fragment consists of amino acids 25-928 of the MET ectodomain or is an N-terminal fragment of amino acids 25-928 of the MET ectodomain having 495 amino acids.
An isolated MET ectodomain fragment in monomeric form, wherein said MET is SEQ ID NO:
- 1 or the A320V variant thereof and wherein said MET ectodomain fragment consists of amino acids 25-519, 25-567, 25-656, 25-741 or 25-838 of said MET.
Dependencies are inferred from the claim text.